Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camidanlumab Tesirine in Advanced Solid Tumors
NCT03621982Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of camidanlumab tesirine in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 9 more, sponsored by ADC Therapeutics. Primary endpoints: Treatment-emergent Adverse Events up to 3 years, Treatment-emergent Adverse Events by CTCAE Grade up to 3 years and 2 more. Started Nov 2018; status: terminated.
02
Drugs
camidanlumab tesirine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)gastric cancer (GC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03621982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621982.